HLA implementation study – The use of an HLA risk allele panel test to identify people vulnerable to drug hypersensitivity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21376

Enrollment

500

Registered

2021-03-03

Start date

2021-03-04

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug hypersensitivity

Interventions

All patients will be genotyped for 24 HLA risk alleles

Eligibility

Inclusion criteria

Inclusion criteria: • At least 18 years of age • Eligible for a medication verification interview at the LUMC • Can give informed consent • Able to give saliva • Suitable to participate in the opinion of the researcher.

Exclusion criteria

Exclusion criteria: • Pregnant or lactating; • Has already been tested for HLA in the past (e.g. organ donors and recipients)

Design outcomes

Primary

Measure	Time frame
the mean number of HLA risk alleles.	—

Contacts

Public ContactLisanne Manson

Leiden University Medical Center

l.e.n.manson@lumc.nl0715263050

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)